Xsphera Biosciences Inc’s Post

🚀 Exciting News in the World of Antibody Drug Conjugates!🔬 🌟 Dive into the latest edition of ADC Digest for this week of May 2024, where groundbreaking advancements are illuminating the field of Antibody Drug 💊 Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer 💊 FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer 💊 GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates Stay tuned for more updates and breakthroughs in the realm of Antibody-Drug Conjugates! #ADC #MedicalInnovations #CancerResearch  #approval #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

Do you have a great idea for a clinical trial? We provide financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated trials. Our studies focus on remote, decentralized, observational biospecimen trials. We bring the trial to the patient. And we can launch trials quickly, especially compared to standard pharmaceutical industry norms. Your idea + our expertise and resources = a quick, efficient process for increasing lung cancer knowledge. We want to hear from you! Let's cure lung cancer together! #lungcancer #cancer #oncology

Delighted to announce the publication of our article 'Prognostic Biomarkers for Triple-Negative Breast Cancer: A Narrative Review' in the International Journal of Pharmaceutical Sciences. This work sheds light on the critical markers that could revolutionize the prognosis and treatment of triple-negative breast cancer. #BreastCancerAwareness #MedicalResearch #InnovationInHealthcare"

Vidac Pharma has made an important step towards clinical trials for its newest anti-cancer drug, VDA-1275, launching new animal studies into the therapy. VDA-1275 in earlier trials has shown promising results, in combination with standard-of-care treatment. “We achieved exceptionally strong results with VDA-1275 in laboratory testing,” Chief Executive Officer Prof. max herzberg Herzberg said. “We believe VDA-1275 could have a broad application across a wide range of tumors.” To read more about how Vidac Pharma’s novel and non-toxic cancer drugs work, have a look at the science section of the website! https://lnkd.in/eShX_zXX #biotech #oncology #drugdevelopment #bioscience #cancer

What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference

What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference

How will #precisiononcology evolve in the upcoming year? Laksh Aithani, CEO of CHARM Therapeutics, shares his insights on the future of oncology in Scrip Asks' latest feature, "What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances." Laksh predicts significant advancements in precision oncology in 2024, particularly in the development of PRMT5 inhibitors for MTAP-deleted cancers, as well as the introduction of state-of-the-art ROS1 and ALK inhibitors in lung cancer treatments. Discover more about the predictions made by #biopharma leaders regarding the impact of #AI and innovative drug development strategies for 2024: https://lnkd.in/eNRMWRb8 #drugdevelopment #healthcareinnovation #CHARMTherapeutics

🚨 𝐒𝐦𝐚𝐥𝐥 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐁𝐄𝐀𝐓𝐒 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 𝐢𝐧 𝐥𝐚𝐭𝐞 𝐭𝐫𝐢𝐚𝐥! Summit Therapeutics and Akeso Biopharma have made significant strides in the field of oncology with their bispecific antibody, ivonescimab, in a recent phase 3 trial conducted in China. 👉 The trial, named HARMONi-2, demonstrated ivonescimab's superiority over Keytruda (a PD-1 inhibitor) in treating non-small cell lung cancer (NSCLC), particularly in patients with PD-L1-expressing tumors. Ivonescimab showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Keytruda monotherapy. The positive results have sparked optimism among analysts and industry experts, with some calling the trial win a milestone achievement. However, the partners still face challenges in gaining approval outside of China, particularly in the U.S. Read more below 👇 #biotech #oncology #biopharma #bispecifics

Today, February 26, the ESMO Targeted Anticancer Therapies Congress 2024 starts in Paris, France! Take a look at the future of anticancer therapies, with a focus on new targets and agents in early development. If you are onsite, visit our sponsor BeiGene at booth no. 2 to learn about and discuss their innovative approaches. #ESMOTAT24 #clinicalresearch #oncology

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence